Skip to content
DNDi Logo
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • DNDi NORTH AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT US
        • ABOUT US
        • BUSINESS MODEL
        • DNDi‘s POLICIES
        • DNDi WORLDWIDE
        • OUR PEOPLE
        • ANNUAL REPORTS
        • E-NEWS
        • JOB OPPORTUNITIES
        • CONTACT US
    • Close
  • DISEASES & PROJECTS
        • DISEASES
        • SLEEPING SICKNESS
        • LEISHMANIASIS
        • CHAGAS DISEASE
        • PAEDIATRIC HIV
        • FILARIAL DISEASE
        • MYCETOMA
        • HEPATITIS C
        • MALARIA
        • PROJECT PORTFOLIO
        • GLOBAL ANTIBIOTIC R&D PARTNERSHIP (GARDP)
        • TARGET PRODUCT PROFILES
        • CLINICAL TRIALS
        • OPEN INNOVATION PORTAL
    • Close
  • ACHIEVEMENTS
      • DNDi ACHIEVEMENTS
      • ASAQ
        Malaria
      • ASMQ
        Malaria
      • NECT
        Sleeping sickness
      • SSG&PM
        Visceral leishmaniasis
      • PAEDIATRIC BENZNIDAZOLE
        Chagas
      • NEW VL TREATMENTS – ASIA
        Visceral leishmaniasis
      • SUPERBOOSTER THERAPY
        Paediatric HIV/TB
      • FEXINIDAZOLE
        Sleeping sickness
    • Close
  • STRENGTHENING CAPACITY
        • OVERVIEW
        • TECHNOLOGY TRANSFERS
        • CHAGAS PLATFORM
        • HAT PLATFORM
        • LEAP PLATFORM
        • REDELEISH NETWORK
    • Close
  • ADVOCACY
      • ADVOCACY UPDATES
      • ACCESS
      • INTELLECTUAL PROPERTY
    • Close
  • MEDIA CENTRE
        • OVERVIEW
        • NEWS, VIEWS & STORIES
        • PRESS RELEASES
        • PRESS KIT
        • IN THE MEDIA
        • OUR PUBLICATIONS
        • E-NEWS
        • VIDEOS
        • SCIENTIFIC ARTICLES
        • EVENTS
    • Close
  • PARTNERS
      • OVERVIEW
      • BUSINESS MODEL
      • PARTNERS
      • BECOME A DNDi PARTNER
      • RFP
    • Close
  • DONATE
      • DONATE
      • HOW TO HELP
      • DONORS
      • KEY FINANCIAL FIGURES
    • Close
    • Close
  • Home
  • Media Centre
  • Scientific Articles
  • Scientific Articles - VL

Scientific Articles - VL

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

by Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, et al. PLoS Negl Trop Dis, June 2012, 6(6): e1674.

Click here to read the article / PDF

Scientific Articles - VLLeishmaniasis, Treatment

Post navigation

Previous
An image-based high-content screening assay for compounds targeting intracellular ‘leshmania donovani’ amastigotes in human macrophages
Next
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Media Centre

  • Overview
  • News, Views & Stories
    • News
    • Viewpoints
    • Stories
  • Press Releases
    • Press Releases – Other Languages
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
      • 2004
      • 2003
  • Press Kit
  • In the Media
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
    • Radio
    • Television
  • Our Publications
  • E-news
    • Subscribe to E-news
    • Special Editions Archive
  • Videos
  • Scientific Articles
    • Human African Trypanosomiasis (Sleeping Sickness)
    • Visceral Leishmaniasis
    • Cutaneous Leishmaniasis
    • Filarial diseases
    • Chagas Disease
    • Mycetoma
    • Malaria
    • Neglected Diseases
    • Paediatric HIV
    • Hepatitis C
    • GARDP
  • Events
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
      • 2004
      • 2003

Media Centre Search

Category
Diseases
Topic
Year

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Learn More

  • Vision & Mission
  • Business Plan
  • DNDi‘s Model
  • Diseases & Projects
  • Portfolio
  • Treatments
  • Clinical Trials
  • Annual Report
  • Scientific Articles
  • Contact Us

Work with Us

  • Donate
  • Partnership
  • RFP
  • Jobs

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

Newsletter

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close